Landmark Study in Non-Muscle Invasive Bladder Cancer Evaluating Breakthrough Investigational Gene Therapy Nadofaragene Firadenovec Published in The Lancet Oncology

Novel intravesical gene therapy given once every three months studied in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer
Phase 3 clinical trial met its primary endpoint with results demonstrating more than half of patients (53.4% of CIS ± Ta/T1 cohort) achieving a complete response (CR), all by three months¹
45.5% of patients in the CIS ± Ta/T1 cohort who achieved CR continued to remain free of high-grade recurrence at 12 months¹

San Francisco, CA (UroToday.com) — FerGene announced that The Lancet Oncology published the Phase 3 data from the landmark U.S. clinical trial evaluating an investigational gene therapy, nadofaragene firadenovec (rAd-IFN/Syn3), for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). In the study, patients received nadofaragene firadenovec, an intravesical therapy given once every three months that is believed to target the patient’s own bladder wall cells to enhance the body’s natural defenses to fight cancer.¹